HELT: A Potential Cancer Treatment Drug (G391723)

Target Name: HELT

NCBI ID: G391723

HELT

HELT: A Potential Cancer Treatment Drug

HELT (Megane bHLH factor) is a protein that is expressed in various tissues throughout the body, including the brain, heart, liver, and kidneys. It is a member of theHLH factor family, which is a group of proteins that play a critical role in the regulation of gene expression and cell development.

One of the unique features of HELT is its ability to induce cell proliferation and survival. When HELT is administered to cancer cells, it has been shown to promote the growth and survival of these cells, making it a potential drug target for cancer treatment.

In addition to its potential cancer-promoting properties, HELT has also been shown to have a variety of other functions in the body. For example, it has been shown to play a role in the development and maintenance of the blood-brain barrier, which is a barrier that separates the brain from the surrounding blood vessels and helps to protect the brain from harmful substances.

HELT has also been shown to be involved in the regulation of cell death, which is an important process that helps to remove damaged or dysfunctional cells from the body. When HELT is activated, it has been shown to induce cell death, which can be a potential mechanism for its anti-cancer properties.

Another potential mechanism for HELT's anti-cancer properties is its ability to regulate the expression of genes that are involved in cell growth and division. When HELT is expressed in cancer cells, it has been shown to reduce the expression of genes that promote cell growth and division, which can potentially inhibit the growth and survival of these cells.

In addition to its potential cancer-promoting and anti-cancer properties, HELT has also been shown to have a variety of other potential applications in medicine. For example, it has been shown to be involved in the regulation of tissue repair and regeneration, which is important for the treatment of injuries and diseases that affect the body's tissues.

HELT has also been shown to be involved in the regulation of cell signaling pathways, which are the processes that allow cells to communicate with one another and coordinate their activities. When HELT is expressed in cells, it has been shown to regulate the activity of several signaling pathways, including the TGF-β pathway, which is involved in cell growth and differentiation.

In conclusion, HELT is a protein that has a variety of potential applications in medicine, including its potential as a drug target for cancer treatment. Its ability to induce cell proliferation and survival, as well as its involvement in the regulation of cell signaling pathways and tissue repair and regeneration, make it a promising target for researchers to explore further. Further studies are needed to fully understand the mechanisms by which HELT promotes cancer growth and survival, as well as its potential as a drug.

Protein Name: Helt BHLH Transcription Factor

Functions: Transcriptional repressor which binds preferentially to the canonical E box sequence 5'-CACGCG-3'

The "HELT Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HELT comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets